Stryker Co. (NYSE:SYK) Shares Purchased by Consolidated Portfolio Review Corp

Consolidated Portfolio Review Corp raised its position in Stryker Co. (NYSE:SYK) by 3.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 983 shares of the medical technology company’s stock after buying an additional 34 shares during the quarter. Consolidated Portfolio Review Corp’s holdings in Stryker were worth $294,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Farmers & Merchants Trust Co of Chambersburg PA increased its stake in shares of Stryker by 203.3% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the period. Quarry LP acquired a new position in Stryker during the 1st quarter worth approximately $27,000. Freedom Wealth Alliance LLC purchased a new position in shares of Stryker during the 4th quarter worth approximately $26,000. HBC Financial Services PLLC acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $37,000. Finally, Cornerstone Planning Group LLC purchased a new stake in shares of Stryker in the second quarter valued at approximately $38,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE:SYK opened at $342.05 on Monday. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The firm has a 50 day simple moving average of $350.82 and a 200-day simple moving average of $310.95. The firm has a market cap of $130.14 billion, a PE ratio of 41.46, a P/E/G ratio of 2.75 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.19. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. Stryker’s revenue was up 11.8% on a year-over-year basis. During the same period in the previous year, the firm posted $3.00 EPS. On average, equities analysts expect that Stryker Co. will post 11.86 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.94%. The ex-dividend date is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is 38.79%.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the sale, the director now directly owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock valued at $72,845,768 in the last 90 days. 5.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Truist Financial raised their price objective on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research note on Wednesday, January 31st. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research report on Wednesday, January 31st. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and lifted their price target for the company from $315.00 to $360.00 in a research report on Wednesday, January 31st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $360.00 price target on shares of Stryker in a research note on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $338.09.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.